Daratumumab: First Global Approval.
Auckland, New Zealand. In Drugs, Feb 2016
Daratumumab (Darzalex™) is a first-in-class, humanized IgG1κ monoclonal antibody that targets the CD38 epitope and was developed by Janssen Biotech and Genmab.
Prognostic Factors for Chronic Lymphocytic Leukemia.
More papers using
Tucson, United States. In Curr Hematol Malig Rep, Feb 2016
The prognostic information can be categorized into three categories: genetic abnormalities which include 17p, 11q, and immunoglobulin heavy chain variable (IGHV) abnormalities; biochemical abnormalities and cell surface markers which include serum thymidine kinase, β-2-microglobulin, CD49d, CD38, and ZAP-70 levels; and patient characteristics which include sex, age, and performance status.
The chemokine SDF-1, stromal cell–derived factor 1, attracts early stage B cell precursors via the chemokine receptor
In The Journal of Experimental Medicine, 1996
... adhesion molecule (ICAM)-1–PE, and anti-CD20-FITC and -PerCP, anti-CD44-FITC, anti-CD56-FITC, anti-CD62 ligand (L)-FITC, anti-CD3-PerCP, anti-CD14-PE, and anti-CD38-PE from Becton Dickinson ...